APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Inhalation CDMO

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Inhalation CDMO Market Analysis and Forecast 2026-2032

Report ID 173909980225 December 2025200 pages

Choose your research edition.

Industry ResearchInhalation CDMO Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Inhalation CDMO Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Inhalation CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Inhalation CDMO Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Inhalation CDMO Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Inhalation CDMO market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Inhalation CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Inhalation CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Inhalation CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Inhalation CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Inhalation CDMO include Aptar Pharma, Bend Bioscience, Bespak, Catalent, CritiTech, Enteris Biopharma, Experic, HCmed and Hovione, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Inhalation CDMO, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Inhalation CDMO, also provides the revenue of main regions and countries. Of the upcoming market potential for Inhalation CDMO, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Inhalation CDMO revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Inhalation CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Inhalation CDMO revenue, projected growth trends, production technology, application and end-user industry.

Inhalation CDMO Segment by Company

Aptar Pharma

Bend Bioscience

Bespak

Catalent

CritiTech

Enteris Biopharma

Experic

HCmed

Hovione

Iconovo

Kindeva

Lonza

Particle Sciences

Proveris

Recipharm

Renejix

Ritedose

Vectura

Sanner

Inhalation CDMO Segment by Type

Soft Mist Inhalers (SMIs)

Dry Powder Inhalers (DPIs)

Metered Dose Inhalers (MDIs)

Others

Inhalation CDMO Segment by Application

Commercial

Academic Research

Others

Inhalation CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inhalation CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Inhalation CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inhalation CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Inhalation CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Inhalation CDMO company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Inhalation CDMO revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Inhalation CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Soft Mist Inhalers (SMIs) Major Player Table 3. Dry Powder Inhalers (DPIs) Major Player Table 4. Metered Dose Inhalers (MDIs) Major Player Table 5. Others Major Player Table 6. Global Inhalation CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Commercial Major Player Table 8. Academic Research Major Player Table 9. Others Major Player Table 10. Inhalation CDMO Industry Trends Table 11. Inhalation CDMO Industry Drivers Table 12. Inhalation CDMO Industry Opportunities and Challenges Table 13. Inhalation CDMO Industry Restraints Table 14. Global Inhalation CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Inhalation CDMO Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Inhalation CDMO Market Share by Region (2021-2026) Table 17. Global Inhalation CDMO Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Inhalation CDMO Market Share by Region (2027-2032) Table 19. Global Inhalation CDMO Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Inhalation CDMO Revenue Market Share by Players (2021-2026) Table 21. Global Inhalation CDMO Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Inhalation CDMO Key Players Headquarters & Area Served Table 23. Global Inhalation CDMO Players, Product Type & Application Table 24. Global Inhalation CDMO Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Inhalation CDMO by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Inhalation CDMO Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Inhalation CDMO Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Inhalation CDMO Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Inhalation CDMO Revenue Market Share by Type (2021-2026) Table 31. Global Inhalation CDMO Revenue Market Share by Type (2027-2032) Table 32. Global Inhalation CDMO Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Inhalation CDMO Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Inhalation CDMO Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Inhalation CDMO Revenue Market Share by Application (2021-2026) Table 36. Global Inhalation CDMO Revenue Market Share by Application (2027-2032) Table 37. Aptar Pharma Company Information Table 38. Aptar Pharma Business Overview Table 39. Aptar Pharma Inhalation CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Aptar Pharma Inhalation CDMO Product Portfolio Table 41. Aptar Pharma Recent Development Table 42. Bend Bioscience Company Information Table 43. Bend Bioscience Business Overview Table 44. Bend Bioscience Inhalation CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Bend Bioscience Inhalation CDMO Product Portfolio Table 46. Bend Bioscience Recent Development Table 47. Bespak Company Information Table 48. Bespak Business Overview Table 49. Bespak Inhalation CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Bespak Inhalation CDMO Product Portfolio Table 51. Bespak Recent Development Table 52. Catalent Company Information Table 53. Catalent Business Overview Table 54. Catalent Inhalation CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Catalent Inhalation CDMO Product Portfolio Table 56. Catalent Recent Development Table 57. CritiTech Company Information Table 58. CritiTech Business Overview Table 59. CritiTech Inhalation CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. CritiTech Inhalation CDMO Product Portfolio Table 61. CritiTech Recent Development Table 62. Enteris Biopharma Company Information Table 63. Enteris Biopharma Business Overview Table 64. Enteris Biopharma Inhalation CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Enteris Biopharma Inhalation CDMO Product Portfolio Table 66. Enteris Biopharma Recent Development Table 67. Experic Company Information Table 68. Experic Business Overview Table 69. Experic Inhalation CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Experic Inhalation CDMO Product Portfolio Table 71. Experic Recent Development Table 72. HCmed Company Information Table 73. HCmed Business Overview Table 74. HCmed Inhalation CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. HCmed Inhalation CDMO Product Portfolio Table 76. HCmed Recent Development Table 77. Hovione Company Information Table 78. Hovione Business Overview Table 79. Hovione Inhalation CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Hovione Inhalation CDMO Product Portfolio Table 81. Hovione Recent Development Table 82. Iconovo Company Information Table 83. Iconovo Business Overview Table 84. Iconovo Inhalation CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Iconovo Inhalation CDMO Product Portfolio Table 86. Iconovo Recent Development Table 87. Kindeva Company Information Table 88. Kindeva Business Overview Table 89. Kindeva Inhalation CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Kindeva Inhalation CDMO Product Portfolio Table 91. Kindeva Recent Development Table 92. Lonza Company Information Table 93. Lonza Business Overview Table 94. Lonza Inhalation CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Lonza Inhalation CDMO Product Portfolio Table 96. Lonza Recent Development Table 97. Particle Sciences Company Information Table 98. Particle Sciences Business Overview Table 99. Particle Sciences Inhalation CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Particle Sciences Inhalation CDMO Product Portfolio Table 101. Particle Sciences Recent Development Table 102. Proveris Company Information Table 103. Proveris Business Overview Table 104. Proveris Inhalation CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Proveris Inhalation CDMO Product Portfolio Table 106. Proveris Recent Development Table 107. Recipharm Company Information Table 108. Recipharm Business Overview Table 109. Recipharm Inhalation CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Recipharm Inhalation CDMO Product Portfolio Table 111. Recipharm Recent Development Table 112. Renejix Company Information Table 113. Renejix Business Overview Table 114. Renejix Inhalation CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Renejix Inhalation CDMO Product Portfolio Table 116. Renejix Recent Development Table 117. Ritedose Company Information Table 118. Ritedose Business Overview Table 119. Ritedose Inhalation CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Ritedose Inhalation CDMO Product Portfolio Table 121. Ritedose Recent Development Table 122. Vectura Company Information Table 123. Vectura Business Overview Table 124. Vectura Inhalation CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Vectura Inhalation CDMO Product Portfolio Table 126. Vectura Recent Development Table 127. Sanner Company Information Table 128. Sanner Business Overview Table 129. Sanner Inhalation CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Sanner Inhalation CDMO Product Portfolio Table 131. Sanner Recent Development Table 132. North America Inhalation CDMO Revenue by Type (2021-2026) & (US$ Million) Table 133. North America Inhalation CDMO Revenue by Type (2027-2032) & (US$ Million) Table 134. North America Inhalation CDMO Revenue by Application (2021-2026) & (US$ Million) Table 135. North America Inhalation CDMO Revenue by Application (2027-2032) & (US$ Million) Table 136. North America Inhalation CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 137. North America Inhalation CDMO Revenue by Country (2021-2026) & (US$ Million) Table 138. North America Inhalation CDMO Revenue by Country (US$ Million) & (2027-2032) Table 139. Europe Inhalation CDMO Revenue by Type (2021-2026) & (US$ Million) Table 140. Europe Inhalation CDMO Revenue by Type (2027-2032) & (US$ Million) Table 141. Europe Inhalation CDMO Revenue by Application (2021-2026) & (US$ Million) Table 142. Europe Inhalation CDMO Revenue by Application (2027-2032) & (US$ Million) Table 143. Europe Inhalation CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 144. Europe Inhalation CDMO Revenue by Country (2021-2026) & (US$ Million) Table 145. Europe Inhalation CDMO Revenue by Country (US$ Million) & (2027-2032) Table 146. China Inhalation CDMO Revenue by Type (2021-2026) & (US$ Million) Table 147. China Inhalation CDMO Revenue by Type (2027-2032) & (US$ Million) Table 148. China Inhalation CDMO Revenue by Application (2021-2026) & (US$ Million) Table 149. China Inhalation CDMO Revenue by Application (2027-2032) & (US$ Million) Table 150. Asia Inhalation CDMO Revenue by Type (2021-2026) & (US$ Million) Table 151. Asia Inhalation CDMO Revenue by Type (2027-2032) & (US$ Million) Table 152. Asia Inhalation CDMO Revenue by Application (2021-2026) & (US$ Million) Table 153. Asia Inhalation CDMO Revenue by Application (2027-2032) & (US$ Million) Table 154. Asia Inhalation CDMO Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 155. Asia Inhalation CDMO Revenue by Region (US$ Million) & (2021-2026) Table 156. Asia Inhalation CDMO Revenue by Region (US$ Million) & (2027-2032) Table 157. SAMEA Inhalation CDMO Revenue by Type (2021-2026) & (US$ Million) Table 158. SAMEA Inhalation CDMO Revenue by Type (2027-2032) & (US$ Million) Table 159. SAMEA Inhalation CDMO Revenue by Application (2021-2026) & (US$ Million) Table 160. SAMEA Inhalation CDMO Revenue by Application (2027-2032) & (US$ Million) Table 161. SAMEA Inhalation CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 162. SAMEA Inhalation CDMO Revenue by Country (2021-2026) & (US$ Million) Table 163. SAMEA Inhalation CDMO Revenue by Country (US$ Million) & (2027-2032) Table 164. Research Programs/Design for This Report Table 165. Authors List of This Report Table 166. Secondary Sources Table 167. Primary Sources List of Figures Figure 1. Inhalation CDMO Image Figure 2. Global Inhalation CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Inhalation CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 4. Soft Mist Inhalers (SMIs) Image Figure 5. Dry Powder Inhalers (DPIs) Image Figure 6. Metered Dose Inhalers (MDIs) Image Figure 7. Others Image Figure 8. Global Inhalation CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Inhalation CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 10. Commercial Image Figure 11. Academic Research Image Figure 12. Others Image Figure 13. Global Inhalation CDMO Market Size (US$ Million) & (2021-2032) Figure 14. Global Inhalation CDMO Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Inhalation CDMO Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Inhalation CDMO Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Inhalation CDMO Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Inhalation CDMO Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Inhalation CDMO Revenue Market Share by Type (2021-2032) Figure 21. Global Inhalation CDMO Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Inhalation CDMO Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Inhalation CDMO Revenue Market Share by Application (2021-2032) Figure 24. North America Inhalation CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Inhalation CDMO Revenue Share by Type (2021-2032) Figure 26. North America Inhalation CDMO Revenue Share by Application (2021-2032) Figure 27. North America Inhalation CDMO Revenue Share by Country (2021-2032) Figure 28. United States Inhalation CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Inhalation CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Inhalation CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Inhalation CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Inhalation CDMO Revenue Share by Type (2021-2032) Figure 33. Europe Inhalation CDMO Revenue Share by Application (2021-2032) Figure 34. Europe Inhalation CDMO Revenue Share by Country (2021-2032) Figure 35. Germany Inhalation CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Inhalation CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Inhalation CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Inhalation CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Inhalation CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Inhalation CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Inhalation CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Inhalation CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Inhalation CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Inhalation CDMO Revenue Share by Type (2021-2032) Figure 45. China Inhalation CDMO Revenue Share by Application (2021-2032) Figure 46. Asia Inhalation CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Inhalation CDMO Revenue Share by Type (2021-2032) Figure 48. Asia Inhalation CDMO Revenue Share by Application (2021-2032) Figure 49. Asia Inhalation CDMO Revenue Share by Region (2021-2032) Figure 50. Japan Inhalation CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Inhalation CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Inhalation CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Inhalation CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Inhalation CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Inhalation CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Inhalation CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Inhalation CDMO Revenue Share by Type (2021-2032) Figure 58. SAMEA Inhalation CDMO Revenue Share by Application (2021-2032) Figure 59. SAMEA Inhalation CDMO Revenue Share by Country (2021-2032) Figure 60. Brazil Inhalation CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Inhalation CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Inhalation CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Inhalation CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Inhalation CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Inhalation CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Inhalation CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Inhalation CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Inhalation CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Inhalation CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Inhalation CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Soft Mist Inhalers (SMIs)
  • Dry Powder Inhalers (DPIs)
  • Metered Dose Inhalers (MDIs)
  • Others
Applications
  • Commercial
  • Academic Research
  • Others
Companies covered
  • Aptar Pharma
  • Bend Bioscience
  • Bespak
  • Catalent
  • CritiTech
  • Enteris Biopharma
  • Experic
  • HCmed
  • Hovione
  • Iconovo
  • Kindeva
  • Lonza
  • Particle Sciences
  • Proveris
  • Recipharm
  • Renejix
  • Ritedose
  • Vectura
  • Sanner

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Inhalation CDMO Market by Type
  3. 1.2.1 Global Inhalation CDMO Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Soft Mist Inhalers (SMIs)
  5. 1.2.3 Dry Powder Inhalers (DPIs)
  6. 1.2.4 Metered Dose Inhalers (MDIs)
  7. 1.2.5 Others
  8. 1.3 Inhalation CDMO Market by Application
  9. 1.3.1 Global Inhalation CDMO Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Commercial
  11. 1.3.3 Academic Research
  12. 1.3.4 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Inhalation CDMO Market Dynamics
  1. 2.1 Inhalation CDMO Industry Trends
  2. 2.2 Inhalation CDMO Industry Drivers
  3. 2.3 Inhalation CDMO Industry Opportunities and Challenges
  4. 2.4 Inhalation CDMO Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Inhalation CDMO Market Perspective (2021-2032)
  2. 3.2 Global Inhalation CDMO Growth Trends by Region
  3. 3.2.1 Global Inhalation CDMO Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Inhalation CDMO Market Size by Region (2021-2026)
  5. 3.2.3 Global Inhalation CDMO Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Inhalation CDMO Revenue by Players
  2. 4.1.1 Global Inhalation CDMO Revenue by Players (2021-2026)
  3. 4.1.2 Global Inhalation CDMO Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Inhalation CDMO Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Inhalation CDMO Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Inhalation CDMO Key Players Headquarters & Area Served
  7. 4.4 Global Inhalation CDMO Players, Product Type & Application
  8. 4.5 Global Inhalation CDMO Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Inhalation CDMO Market CR5 and HHI
  11. 4.6.3 2025 Inhalation CDMO Tier 1, Tier 2, and Tier 3
5 Inhalation CDMO Market Size by Type
  1. 5.1 Global Inhalation CDMO Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Inhalation CDMO Revenue by Type (2021-2032)
  3. 5.3 Global Inhalation CDMO Revenue Market Share by Type (2021-2032)
6 Inhalation CDMO Market Size by Application
  1. 6.1 Global Inhalation CDMO Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Inhalation CDMO Revenue by Application (2021-2032)
  3. 6.3 Global Inhalation CDMO Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Aptar Pharma
  2. 7.1.1 Aptar Pharma Company Information
  3. 7.1.2 Aptar Pharma Business Overview
  4. 7.1.3 Aptar Pharma Inhalation CDMO Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Aptar Pharma Inhalation CDMO Product Portfolio
  6. 7.1.5 Aptar Pharma Recent Developments
  7. 7.2 Bend Bioscience
  8. 7.2.1 Bend Bioscience Company Information
  9. 7.2.2 Bend Bioscience Business Overview
  10. 7.2.3 Bend Bioscience Inhalation CDMO Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Bend Bioscience Inhalation CDMO Product Portfolio
  12. 7.2.5 Bend Bioscience Recent Developments
  13. 7.3 Bespak
  14. 7.3.1 Bespak Company Information
  15. 7.3.2 Bespak Business Overview
  16. 7.3.3 Bespak Inhalation CDMO Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Bespak Inhalation CDMO Product Portfolio
  18. 7.3.5 Bespak Recent Developments
  19. 7.4 Catalent
  20. 7.4.1 Catalent Company Information
  21. 7.4.2 Catalent Business Overview
  22. 7.4.3 Catalent Inhalation CDMO Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Catalent Inhalation CDMO Product Portfolio
  24. 7.4.5 Catalent Recent Developments
  25. 7.5 CritiTech
  26. 7.5.1 CritiTech Company Information
  27. 7.5.2 CritiTech Business Overview
  28. 7.5.3 CritiTech Inhalation CDMO Revenue and Gross Margin (2021-2026)
  29. 7.5.4 CritiTech Inhalation CDMO Product Portfolio
  30. 7.5.5 CritiTech Recent Developments
  31. 7.6 Enteris Biopharma
  32. 7.6.1 Enteris Biopharma Company Information
  33. 7.6.2 Enteris Biopharma Business Overview
  34. 7.6.3 Enteris Biopharma Inhalation CDMO Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Enteris Biopharma Inhalation CDMO Product Portfolio
  36. 7.6.5 Enteris Biopharma Recent Developments
  37. 7.7 Experic
  38. 7.7.1 Experic Company Information
  39. 7.7.2 Experic Business Overview
  40. 7.7.3 Experic Inhalation CDMO Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Experic Inhalation CDMO Product Portfolio
  42. 7.7.5 Experic Recent Developments
  43. 7.8 HCmed
  44. 7.8.1 HCmed Company Information
  45. 7.8.2 HCmed Business Overview
  46. 7.8.3 HCmed Inhalation CDMO Revenue and Gross Margin (2021-2026)
  47. 7.8.4 HCmed Inhalation CDMO Product Portfolio
  48. 7.8.5 HCmed Recent Developments
  49. 7.9 Hovione
  50. 7.9.1 Hovione Company Information
  51. 7.9.2 Hovione Business Overview
  52. 7.9.3 Hovione Inhalation CDMO Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Hovione Inhalation CDMO Product Portfolio
  54. 7.9.5 Hovione Recent Developments
  55. 7.10 Iconovo
  56. 7.10.1 Iconovo Company Information
  57. 7.10.2 Iconovo Business Overview
  58. 7.10.3 Iconovo Inhalation CDMO Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Iconovo Inhalation CDMO Product Portfolio
  60. 7.10.5 Iconovo Recent Developments
  61. 7.11 Kindeva
  62. 7.11.1 Kindeva Company Information
  63. 7.11.2 Kindeva Business Overview
  64. 7.11.3 Kindeva Inhalation CDMO Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Kindeva Inhalation CDMO Product Portfolio
  66. 7.11.5 Kindeva Recent Developments
  67. 7.12 Lonza
  68. 7.12.1 Lonza Company Information
  69. 7.12.2 Lonza Business Overview
  70. 7.12.3 Lonza Inhalation CDMO Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Lonza Inhalation CDMO Product Portfolio
  72. 7.12.5 Lonza Recent Developments
  73. 7.13 Particle Sciences
  74. 7.13.1 Particle Sciences Company Information
  75. 7.13.2 Particle Sciences Business Overview
  76. 7.13.3 Particle Sciences Inhalation CDMO Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Particle Sciences Inhalation CDMO Product Portfolio
  78. 7.13.5 Particle Sciences Recent Developments
  79. 7.14 Proveris
  80. 7.14.1 Proveris Company Information
  81. 7.14.2 Proveris Business Overview
  82. 7.14.3 Proveris Inhalation CDMO Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Proveris Inhalation CDMO Product Portfolio
  84. 7.14.5 Proveris Recent Developments
  85. 7.15 Recipharm
  86. 7.15.1 Recipharm Company Information
  87. 7.15.2 Recipharm Business Overview
  88. 7.15.3 Recipharm Inhalation CDMO Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Recipharm Inhalation CDMO Product Portfolio
  90. 7.15.5 Recipharm Recent Developments
  91. 7.16 Renejix
  92. 7.16.1 Renejix Company Information
  93. 7.16.2 Renejix Business Overview
  94. 7.16.3 Renejix Inhalation CDMO Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Renejix Inhalation CDMO Product Portfolio
  96. 7.16.5 Renejix Recent Developments
  97. 7.17 Ritedose
  98. 7.17.1 Ritedose Company Information
  99. 7.17.2 Ritedose Business Overview
  100. 7.17.3 Ritedose Inhalation CDMO Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Ritedose Inhalation CDMO Product Portfolio
  102. 7.17.5 Ritedose Recent Developments
  103. 7.18 Vectura
  104. 7.18.1 Vectura Company Information
  105. 7.18.2 Vectura Business Overview
  106. 7.18.3 Vectura Inhalation CDMO Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Vectura Inhalation CDMO Product Portfolio
  108. 7.18.5 Vectura Recent Developments
  109. 7.19 Sanner
  110. 7.19.1 Sanner Company Information
  111. 7.19.2 Sanner Business Overview
  112. 7.19.3 Sanner Inhalation CDMO Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Sanner Inhalation CDMO Product Portfolio
  114. 7.19.5 Sanner Recent Developments
8 North America
  1. 8.1 North America Inhalation CDMO Revenue (2021-2032)
  2. 8.2 North America Inhalation CDMO Revenue by Type (2021-2032)
  3. 8.2.1 North America Inhalation CDMO Revenue by Type (2021-2026)
  4. 8.2.2 North America Inhalation CDMO Revenue by Type (2027-2032)
  5. 8.3 North America Inhalation CDMO Revenue Share by Type (2021-2032)
  6. 8.4 North America Inhalation CDMO Revenue by Application (2021-2032)
  7. 8.4.1 North America Inhalation CDMO Revenue by Application (2021-2026)
  8. 8.4.2 North America Inhalation CDMO Revenue by Application (2027-2032)
  9. 8.5 North America Inhalation CDMO Revenue Share by Application (2021-2032)
  10. 8.6 North America Inhalation CDMO Revenue by Country
  11. 8.6.1 North America Inhalation CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Inhalation CDMO Revenue by Country (2021-2026)
  13. 8.6.3 North America Inhalation CDMO Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Inhalation CDMO Revenue (2021-2032)
  2. 9.2 Europe Inhalation CDMO Revenue by Type (2021-2032)
  3. 9.2.1 Europe Inhalation CDMO Revenue by Type (2021-2026)
  4. 9.2.2 Europe Inhalation CDMO Revenue by Type (2027-2032)
  5. 9.3 Europe Inhalation CDMO Revenue Share by Type (2021-2032)
  6. 9.4 Europe Inhalation CDMO Revenue by Application (2021-2032)
  7. 9.4.1 Europe Inhalation CDMO Revenue by Application (2021-2026)
  8. 9.4.2 Europe Inhalation CDMO Revenue by Application (2027-2032)
  9. 9.5 Europe Inhalation CDMO Revenue Share by Application (2021-2032)
  10. 9.6 Europe Inhalation CDMO Revenue by Country
  11. 9.6.1 Europe Inhalation CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Inhalation CDMO Revenue by Country (2021-2026)
  13. 9.6.3 Europe Inhalation CDMO Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Inhalation CDMO Revenue (2021-2032)
  2. 10.2 China Inhalation CDMO Revenue by Type (2021-2032)
  3. 10.2.1 China Inhalation CDMO Revenue by Type (2021-2026)
  4. 10.2.2 China Inhalation CDMO Revenue by Type (2027-2032)
  5. 10.3 China Inhalation CDMO Revenue Share by Type (2021-2032)
  6. 10.4 China Inhalation CDMO Revenue by Application (2021-2032)
  7. 10.4.1 China Inhalation CDMO Revenue by Application (2021-2026)
  8. 10.4.2 China Inhalation CDMO Revenue by Application (2027-2032)
  9. 10.5 China Inhalation CDMO Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Inhalation CDMO Revenue (2021-2032)
  2. 11.2 Asia Inhalation CDMO Revenue by Type (2021-2032)
  3. 11.2.1 Asia Inhalation CDMO Revenue by Type (2021-2026)
  4. 11.2.2 Asia Inhalation CDMO Revenue by Type (2027-2032)
  5. 11.3 Asia Inhalation CDMO Revenue Share by Type (2021-2032)
  6. 11.4 Asia Inhalation CDMO Revenue by Application (2021-2032)
  7. 11.4.1 Asia Inhalation CDMO Revenue by Application (2021-2026)
  8. 11.4.2 Asia Inhalation CDMO Revenue by Application (2027-2032)
  9. 11.5 Asia Inhalation CDMO Revenue Share by Application (2021-2032)
  10. 11.6 Asia Inhalation CDMO Revenue by Country
  11. 11.6.1 Asia Inhalation CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Inhalation CDMO Revenue by Country (2021-2026)
  13. 11.6.3 Asia Inhalation CDMO Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Inhalation CDMO Revenue (2021-2032)
  2. 12.2 SAMEA Inhalation CDMO Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Inhalation CDMO Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Inhalation CDMO Revenue by Type (2027-2032)
  5. 12.3 SAMEA Inhalation CDMO Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Inhalation CDMO Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Inhalation CDMO Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Inhalation CDMO Revenue by Application (2027-2032)
  9. 12.5 SAMEA Inhalation CDMO Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Inhalation CDMO Revenue by Country
  11. 12.6.1 SAMEA Inhalation CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Inhalation CDMO Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Inhalation CDMO Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst